$234.47
0.41[0.18%]
At close: Apr 23
$234.47
0[0.00%]
After Hours: 4:04PM EDT
United Therapeutics
(NASDAQ:UTHR)United Therapeutics Stock (NASDAQ:UTHR), Analyst Ratings, Price Targets, Predictions
United Therapeutics Corp has a consensus price target of $271.73, established from looking at the 39 latest analyst ratings. The last 3 analyst ratings were released from Wells Fargo, Wedbush, and HC Wainwright & Co. on March 7, 2024, February 22, 2024, and February 22, 2024. With an average price target of $311 between Wells Fargo, Wedbush, and HC Wainwright & Co., there's an implied 32.64% upside for United Therapeutics Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Wedbush
HC Wainwright & Co.
Goldman Sachs
Leerink Partners
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for United Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/07/2024 | UTHR | Buy Now | United Therapeutics | $234.47 | 38.61% | Wells Fargo | Tiago Fauth | $309 → $325 | Maintains | Overweight | Get Alert |
| 02/22/2024 | UTHR | Buy Now | United Therapeutics | $234.47 | 31.36% | Wedbush | Liana Moussatos | → $308 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | UTHR | Buy Now | United Therapeutics | $234.47 | 27.95% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2024 | UTHR | Buy Now | United Therapeutics | $234.47 | -8.3% | Goldman Sachs | Chris Shibutani | $213 → $215 | Upgrade | Sell → Neutral | Get Alert |
| 02/05/2024 | UTHR | Buy Now | United Therapeutics | $234.47 | 40.74% | Leerink Partners | Roanna Ruiz | → $330 | Initiates | → Outperform | Get Alert |
| 11/02/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 25.39% | JP Morgan | Jessica Fung | $290 → $294 | Maintains | Overweight | Get Alert |
| 11/02/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 33.92% | Morgan Stanley | Terence Flynn | $318 → $314 | Maintains | Overweight | Get Alert |
| 11/02/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 31.36% | Wedbush | Liana Moussatos | $307 → $308 | Maintains | Outperform | Get Alert |
| 08/03/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 35.63% | Morgan Stanley | Terence Flynn | $316 → $318 | Maintains | Overweight | Get Alert |
| 08/03/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 14.3% | Ladenburg Thalmann | Matthew Kaplan | $256 → $268 | Maintains | Buy | Get Alert |
| 08/03/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 30.93% | Wedbush | Liana Moussatos | $305 → $307 | Maintains | Outperform | Get Alert |
| 08/03/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 27.95% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | Buy → Buy | Get Alert |
| 05/04/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 9.18% | Ladenburg Thalmann | Matthew Kaplan | $285 → $256 | Maintains | Buy | Get Alert |
| 04/21/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 19.42% | Argus Research | Jasper Hellweg | $300 → $280 | Maintains | Buy | Get Alert |
| 04/10/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 32.21% | UBS | Ashwani Verma | $330 → $310 | Maintains | Buy | Get Alert |
| 04/10/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 34.77% | Morgan Stanley | Terence Flynn | $320 → $316 | Maintains | Overweight | Get Alert |
| 02/23/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 19.42% | JP Morgan | Jessica Fung | $265 → $280 | Maintains | Overweight | Get Alert |
| 02/23/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 36.48% | Morgan Stanley | Terence Flynn | $330 → $320 | Maintains | Overweight | Get Alert |
| 02/23/2023 | UTHR | Buy Now | United Therapeutics | $234.47 | 27.95% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for United Therapeutics (UTHR)?
The latest price target for United Therapeutics (NASDAQ: UTHR) was reported by Wells Fargo on March 7, 2024. The analyst firm set a price target for $325.00 expecting UTHR to rise to within 12 months (a possible 38.61% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for United Therapeutics (UTHR)?
The latest analyst rating for United Therapeutics (NASDAQ: UTHR) was provided by Wells Fargo, and United Therapeutics maintained their overweight rating.
When was the last upgrade for United Therapeutics (UTHR)?
The last upgrade for United Therapeutics Corp happened on February 12, 2024 when Goldman Sachs raised their price target to $215. Goldman Sachs previously had a sell for United Therapeutics Corp.
When was the last downgrade for United Therapeutics (UTHR)?
There is no last downgrade for United Therapeutics.
When is the next analyst rating going to be posted or updated for United Therapeutics (UTHR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on March 7, 2024 so you should expect the next rating to be made available sometime around March 7, 2025.
Is the Analyst Rating United Therapeutics (UTHR) correct?
While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a maintained with a price target of $309.00 to $325.00. The current price United Therapeutics (UTHR) is trading at is $234.47, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.